Collectively, these experimental findings establish a direct mechanistic link between LSD1 inhibition and enhanced tumor immunogenicity, providing a solid biological rationale for combining LSD1 inhibitors with immune checkpoint inhibitors in future therapeutic strategies. Here, KDM1A is linked to neoplasm.